Gene expression associated with acquired paclitaxel resistance in ovarian cancer cell lines

Conventional frontline treatment for ovarian cancer consists of successive chemotherapy cycles of paclitaxel and platinum. Despite the initial favorable responses for most patients, chemotherapy resistance frequently leads to recurrent or refractory disease. New treatment strategies that circumvent or prevent mechanisms of resistance are needed to improve ovarian cancer therapy. We developed in vitro ovarian cancer cell line models of acquired paclitaxel resistance using 2 immortalized human ovarian cancer cell lines, OVCAR3 and TOV-21G. We also developed in vitro primary ovarian cancer organoid models using tumor tissue from 7 patients with gynecologic malignancies. Gene expression differences in resistant and sensitive lines were analyzed by RNA sequencing to identify potential mechanisms of paclitaxel resistance in primary ovarian cancer. Overall design: Paclitaxel-resistant and parental control cells derived from 2 distinct ovarian cancer cell lines, each analyzed in triplicate (12 total samples). Paclitaxel-resistant (n=3) and sensitive (n=4) organoids derived from 7 primary ovarian tumor tissue samples